Altimmune to Announce First Quarter 2020 Financial Results on May 14
Conference Call Details | ||
Date: | ||
Time: | ||
Domestic: | 855-327-6837 | |
International: | 631-891-4304 | |
Conference ID: | 10009533 | |
Webcast: | http://public.viavid.com/index.php?id=139687 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.
Contacts: | ||
Chief Financial Officer | ||
Phone: 240-654-1450 | 617-430-7577 | |
wbrown@altimmune.com | arr@lifesciadvisors.com |
Source: Altimmune, Inc.